From 1992 to 2015, the number of deaths due to cervical cancer among U.S. women under the age of 25 fell steadily from each three-year period to the next, dropping roughly 75% altogether over that span. The sharp decline in cervical cancer deaths is likely due, at least in part, to the widespread introduction of the HPV vaccine in 2006.
Researchers at University of California San Francisco (UCSF) have developed a single genomic test that can quickly detect virtually any kind of pathogen in a patient. This allows for much quicker diagnoses, enables targeted treatment to begin sooner, and could lower healthcare costs. Over the course of 7 years, researchers led by UCSF professor Charles Chiu tested 4,828 patients’ samples with its clinical mNGS method. The mNGS test accurately identified 86% of neurological infections.
Pneumonia kills 2,000 children under five worldwide every day, making it the world’s biggest infectious cause of death in children. The introduction of pneumococcal conjugate vaccines (PCVs) has significantly lowered the burden of death and disease from pneumonia, but millions of children remain unvaccinated. Since the public-private global health partnership Gavi supported the first roll-out of the PCV vaccine in 2009, 438 million children of all ages have been vaccinated in 64 countries, averting an estimated total of 1.2 million deaths by the end of 2023.
Kohji Nishida, an ophthalmologist at Osaka University in Japan, and his colleagues used an alternative source of cells — induced pluripotent stem (iPS) cells — to make the corneal transplants. They took blood cells from a healthy donor and reprogrammed them into an embryonic-like state, then transformed them into a thin, transparent sheet of cobblestone-shaped corneal epithelial cells. After the transplants, all four recipients showed immediate improvements in their vision and a reduction in the area of the cornea affected by limbal stem-cell deficiency. The improvements persisted in all but one recipient, who showed slight reversals during a one-year observation period.
Malaria remains a leading cause of childhood mortality in Sudan, which has one of the highest malaria rates in the region. The disease claimed an estimated 7,900 lives in Sudan in 2023, though the actual toll may be higher due to ongoing conflict between rival militaries. The launch follows the arrival of the first consignment of 186,000 doses to Sudan in October and the campaign will begin across 15 health facilities in Gedaref and the Blue Nile states, benefitting more than 148,000 children under 12 months-old. In 2025 and 2026, the vaccine will be introduced in a further 129 localities.
The Biden-Harris administration has announced a new requirement for insurance providers to cover injectable PrEP in their policies without a co-payment for consumers. The new rule, built on previous guidance for the Affordable Care Act, also applies to increased choice in contraception. The Biden-Harris administration announced Monday a new requirement for insurance providers to cover injectable PrEP in their policies without a co-payment for consumers. PrEP, or pre-exposure prophylaxis, was first approved by the FDA in 2012 to prevent people exposed to HIV from becoming infected with the virus. Truvada in pill form was the first prescriptive PrEP to hit the market, followed by Descovy. The injectable PrEP Apretude was approved in 2021.
The World Health Organization (WHO) has certified Egypt as malaria-free, marking a significant public health milestone for a country with more than 100 million inhabitants. The achievement follows a nearly 100-year effort by the Egyptian government and people to end a disease that has been present in the country since ancient times. Egypt is the third country to be awarded a malaria-free certification in the WHO Eastern Mediterranean Region following the United Arab Emirates and Morocco, and the first since 2010. Globally, a total of 44 countries and 1 territory have reached this milestone.
For decades, researchers have been working to develop a system that can automatically adjust insulin activity based on the amount of glucose in a person’s blood. Now, Rita Slaaby, a principal scientist at pharmaceutical company Novo Nordisk in Bagsværd, Denmark, and her colleagues engineered an insulin molecule with a switch that turns its activity on and off in response to glucose levels in the blood. In animals, this ‘smart’ insulin reduces high blood-sugar concentrations effectively while preventing levels from dropping too low.
New research from Amsterdam University Medical Center introduces a promising new treatment approach for type 2 diabetes (T2D) that has the potential to greatly reduce or even eliminate the need for insulin therapy. This innovative approach, which combines a novel procedure known as ReCET (Re-Cellularization via Electroporation Therapy) with semaglutide, resulted in the elimination of insulin therapy for 86% of the 14 patients participating in initial trials. Globally, T2D affects 422 million people. While insulin therapy is commonly used to manage blood sugar levels in T2D patients, it can result in side effects such as weight gain and further complicate diabetes management.
Someone presenting to the emergency room with a suspected heart attack will undergo a number of standard blood tests to determine heart muscle damage. The problem is that it can take one or two hours to receive the results. Now, Johns Hopkins University researchers have led the design of a tiny chip that diagnoses heart attack by detecting these important biomarkers in minutes rather than hours, even if they are present at very low concentrations. The researchers foresee an at-home heart attack detector in the future.
